Goldman Sachs analyst James Quigley maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of ...

Analyst Eric Le Berrigaud from Stifel Nicolaus maintained a Hold rating on Novartis AG (NOVN – Research Report) and keeping the price ...

Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But on Tuesday, the Food and Drug Administration approved ...

Novartis AG’s breast cancer drug helped prevent the disease coming back a year after treatment had ended, in new data that will be closely compared with a rival product from Eli Lilly. Novartis ...

Drugmakers at the top of the list were Astellas, AstraZeneca, Daiichi Sankyo, Gilead Sciences and Novartis. The five companies accounted for 71% of the high-benefit approvals over the past four years.

Today, the Lonza Board of Directors announced the nomination of Juan Andres and Eric Drapé as Independent Members of the Board. The Board will propose to shareholders the election of both nominees at ...

The FDA yesterday approved Novartis’ Kisqali in combination with hormone therapy for patients with certain early-stage breast cancers, significantly expanding the number of patients who will ...

Aug 24 (Reuters) - Swiss drugmaker Novartis (NOVN.S), opens new tab said on Saturday it had received a binding offer from Germany's Siemens Healthineers (SHLG.DE), opens new tab to acquire its ...

Novartis’ blood cancer sculpture tour has reached a new destination. The Swiss drugmaker, which put the sculptures on show in London one year ago, is marking this year’s Blood Cancer Awareness ...

Siemens Healthineers aims to grow its PET imaging business by picking up the radiodiagnostic manufacturing and distribution network of Novartis’ Advanced Accelerator Applications division.

The BTK inhibitors market is poised for remarkable growth driven by advancements in oncology and autoimmune disease treatments. With expanding research and development efforts, these inhibitors ...

Siemens Healthineers is planning to purchase the diagnostic arm of Novartis’ Advanced Accelerator Applications (AAA), for a sum exceeding €200m ($224m), reported Financial Times (FT).